The Technical Analyst
Bicycle Therapeutics PLC [BCYC]
Exchange: NasdaqGS Sector: Healthcare Industry: Biotechnology
Bicycle Therapeutics PLC Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
4.23% $17.49
Last updated: 3 jul 2022 - 19:56
TimeZone: America/New_York
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 518.55 mill |
| EPS: | -2.91 |
| P/E: | 0.000 |
| Earnings Date: | Aug 03, 2022 |
| SharesOutstanding: | 29.65 mill |
| Avg Daily Volume: | 0.663 mill |
| RATING 2022-07-01 |
|---|
| B+ |
| Buy |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Neutral | |
| Return On Asset: | Neutral | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/20 | 1/21 | 2/21 | 3/21 | 4/21 | 1/22 | |
| Revenue | ||||||
| Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
| Ebit | ||||||
| Asset | ||||||
| Debt |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$34.99 (100.08%) $17.50 |
| Date: 2022-07-03 |
| True Range Average |
|---|
|
+/- $1.538 ( +/- 8.79%) Range: 15.95 - 19.03 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-03-25 | Milnes Alistair | Buy | 5 155 | Employee Stock Option (right to buy) |
| 2022-03-25 | Milnes Alistair | Buy | 5 155 | Ordinary Shares |
| 2022-01-03 | Jordan Veronica Gh | Buy | 10 000 | Stock Option (right to buy) |
| 2022-01-03 | Jordan Veronica Gh | Buy | 5 000 | Ordinary Shares |
| 2022-01-03 | Winter Gregory Paul | Buy | 10 000 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 21.69 |
| Last 100 transactions |
| Buy: 886 197 | Sell: 585 669 |
Forecast:
16:00 - $17.49
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $17.49
Forecast 2: 16:00 - $17.49
Forecast 3: 16:00 - $17.49
SCORE
-10.00
Sell
-10.00
Sell
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $17.49 (4.23% ) |
| Volume | 0.142 mill |
| Avg. Vol. | 0.663 mill |
| % of Avg. Vol | 21.46 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For BCYC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since 31-12-69
| Date | Signal | @ | Closed | % | Jun 28 - 16:58 | sell | $17.00 | N/A | Active |
|---|
BCYC
Bicycle Therapeutics Plc is a holding company, which engages in the development of biopharmaceuticals. The company is headquartered in Cambridge, Cambridgeshire and currently employs 61 full-time employees. The firm is focused on developing a class of medicines for diseases. The Company’s lead product candidate, BT1718, is a Bicycle Toxin Conjugate (BTC) for oncology indications. BT1718 targets tumors that express Membrane Type 1 matrix metalloprotease (MT1-MMP). The firm is also developing BT5528 and BT8009, which are BTCs targeting Ephrin type-A receptor 2 (EphA2), and Nectin-4, for oncology indications. The firm is also developing cytotoxic T-cell activators, designed to trigger an immune response to tumors.
Latest Press Releases
2022-06-08 07:00:00 - Press Release
Bicycle Therapeutics Announces First Patient Dosed In Expansion Cohorts Of Phase I/ii Trial Of Bicycle® Toxin Conjugate Bt5528 In Patients With Advanced Solid Tumors Associated With Epha2 Expression
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced the first patient has been dosed in the expansion portion of the phase i/ii study of bt5528, bicycle's second-generation bicycle toxin conjugate (btc™) targeting epha2. “we believe epha2 is an attractive target for cytotoxin delivery and bt5528 has
2022-06-01 07:00:00 - Press Release
Bicycle Therapeutics To Participate In The Jefferies Healthcare Conference
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that management will participate in a fireside chat at the jefferies healthcare conference in new york, ny on wednesday, june 8, 2022 at 8:00 a.m. et. a live webcast of the fireside chat will be accessible in the investors and media section of bicyc
2022-03-08 16:35:00 - Press Release
Bicycle Therapeutics Announces Interim Bt8009 Phase I Clinical Trial Results Selected For An Oral Presentation At The 2022 Aacr Annual Meeting
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that interim phase i results from the phase i/ii trial of bt8009, a second-generation btc™ targeting nectin-4, has been selected for an oral presentation at the upcoming 2022 american association for cancer research annual meeting, being held april
2022-03-08 07:00:00 - Press Release
Bicycle Therapeutics To Participate In The Oppenheimer 32nd Annual Healthcare Conference
Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that management will participate in a fireside chat at the oppenheimer 32nd annual healthcare conference on tuesday, march 15, 2022 at 8:00 a.m. et. the conference will be held in a virtual meeting format. a live webcast of the fireside chat will be
2022-01-05 07:00:00 - Press Release
Bicycle Therapeutics Announces Continued Clinical Progress And Updates To Management Team
Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced continued progress in its ongoing phase i/ii clinical trials of bt8009, bt5528 and bt7480. “last quarter, we reported interim clinical results from ongoing trials of two of our bicycle toxin conjugates, bt8009 and bt5528, demonstrating preliminary